La Jolla grabs $125M royalty deal to back drug launch, fund R&D
La Jolla Pharmaceuticals $LJPC has landed $125 million to back its rollout of Giapreza, a new drug for dangerously low blood pressure that was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
